Zacks Investment Research lowered shares of Diplomat Pharmacy (NYSE:DPLO) from a hold rating to a sell rating in a research note published on Wednesday morning.

According to Zacks, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan. “

DPLO has been the topic of a number of other reports. William Blair cut Diplomat Pharmacy from an outperform rating to a market perform rating in a research note on Monday, January 7th. ValuEngine cut Diplomat Pharmacy from a sell rating to a strong sell rating in a research note on Monday, February 4th. Barclays restated an overweight rating and issued a $8.00 price target (down from $18.00) on shares of Diplomat Pharmacy in a research note on Monday, February 25th. Svb Leerink cut Diplomat Pharmacy from an outperform rating to a market perform rating and cut their price target for the company from $24.00 to $6.00 in a research note on Monday, February 25th. Finally, Leerink Swann cut Diplomat Pharmacy from an outperform rating to a market perform rating and set a $30.00 target price on the stock. in a research report on Monday, February 25th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company’s stock. Diplomat Pharmacy has a consensus rating of Hold and an average target price of $13.78.

Shares of NYSE DPLO opened at $5.55 on Wednesday. The firm has a market capitalization of $413.34 million, a PE ratio of 6.61 and a beta of 0.74. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.66 and a current ratio of 0.95. Diplomat Pharmacy has a 12-month low of $5.16 and a 12-month high of $28.74.

Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings results on Friday, March 15th. The company reported $0.14 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.24 by ($0.10). Diplomat Pharmacy had a net margin of 0.04% and a return on equity of 5.31%. The business had revenue of $1.36 billion during the quarter, compared to analyst estimates of $1.41 billion. During the same quarter in the prior year, the business earned $0.09 earnings per share. The firm’s quarterly revenue was up 17.8% on a year-over-year basis. As a group, analysts anticipate that Diplomat Pharmacy will post 0.8 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Thrivent Financial for Lutherans increased its position in shares of Diplomat Pharmacy by 2.2% during the fourth quarter. Thrivent Financial for Lutherans now owns 39,424 shares of the company’s stock worth $531,000 after purchasing an additional 867 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Diplomat Pharmacy by 43.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,425 shares of the company’s stock worth $46,000 after purchasing an additional 1,037 shares in the last quarter. Texas Permanent School Fund increased its position in shares of Diplomat Pharmacy by 4.1% during the fourth quarter. Texas Permanent School Fund now owns 37,039 shares of the company’s stock worth $499,000 after purchasing an additional 1,458 shares in the last quarter. New York State Common Retirement Fund increased its position in shares of Diplomat Pharmacy by 0.8% during the fourth quarter. New York State Common Retirement Fund now owns 216,819 shares of the company’s stock worth $2,918,000 after purchasing an additional 1,706 shares in the last quarter. Finally, BDO Wealth Advisors LLC acquired a new stake in shares of Diplomat Pharmacy during the fourth quarter worth about $27,000. Institutional investors and hedge funds own 86.58% of the company’s stock.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Featured Article: Gross Domestic Product (GDP)

Get a free copy of the Zacks research report on Diplomat Pharmacy (DPLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.